OXB — Oxford BioMedica Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	64.1	87.7	143	140	89.5
Cost of Revenue
Gross Profit	28.3	46.1	82.6	69.2	39.7
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	78.5	93.4	122	170	274
Operating Profit	-14.5	-5.69	20.8	-30.2	-184
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-20.9	-6.57	19.9	-46	-189
Provision for Income Taxes
Net Income After Taxes	-16.1	-6.25	19	-45.2	-184
Minority Interest
Net Income Before Extraordinary Items
Net Income	-16.1	-6.25	19	-39.2	-157
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-16.1	-6.25	19	-39.2	-157
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.221	-0.078	0.222	-0.56	-0.97
Dividends per Share